Systematic approaches to toxicology in the zebrafish

Annual Review of Pharmacology and Toxicology

Volumn 52, Issue , 2012, Pages 433-453

  Peterson, Randall T ^a   MacRae, Calum A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Drug discovery; Genomics; High throughput screening; Pharmacogenetics; Toxicogenetics

Indexed keywords

ARTICLE; CARCINOGENICITY; CARDIOTOXICITY; DISTRIBUTION VOLUME; DRUG ADSORPTION; DRUG EXCRETION; DRUG METABOLISM; ENVIRONMENTAL FACTOR; GASTROINTESTINAL TOXICITY; GENOME; HUMAN; IN VIVO STUDY; LIVER TOXICITY; MYOTOXICITY; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; SCREENING TEST; TERATOGENICITY; TOXICITY TESTING; TOXICOGENETICS; VERTEBRATE; ZEBRA FISH;

ANIMALS; CARCINOGENICITY TESTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; GASTROINTESTINAL TRACT; HEART; LIVER; MODELS, ANIMAL; MUSCLES; NEURONS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHENOTYPE; TOXICITY TESTS; ZEBRAFISH;

DANIO RERIO;

EID: 84855865117     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010611-134751     Document Type: Article

References (132)

1. Bleicher KH, B̈ohm HJ, M̈uller K, Alanine AI. 2003. Hit and lead generation: beyond high-throughput screening. Nat. Rev. Drug Discov. 2:369-78 (Pubitemid 37361707)
2. Lavery KS, King TH. 2003. Antisense and RNAi: powerful tools in drug target discovery and validation. Curr. Opin. Drug Discov. Dev. 6:561-69 (Pubitemid 36975358)
3. Hack A, Ahouse J, Roberts P, Garakani A. 2004. New methods for automated phenotyping of complex cellular behaviors. Conf. Proc. IEEE Eng. Med. Biol. Soc. 7:5124-26 (Pubitemid 40035011)
4. Pelkonen O, Raunio H. 2005. In vitro screening of drug metabolism during drug development: can we trust the predictions? Expert Opin. Drug Metab. Toxicol. 1:49-59
5. MacRae CA, Peterson RT. 2003. Zebrafish-based small molecule discovery. Chem. Biol. 10:901-8 (Pubitemid 37316907)
6. Zon LI, Peterson RT. 2005. In vivo drug discovery in the zebrafish. Nat. Rev. Drug Discov. 4:35-44 (Pubitemid 40109588)
7. Perrimon N, Friedman A, Mathey-Prevot B, Eggert US. 2007. Drug-target identification in Drosophila cells: combining high-throughput RNAi and small-molecule screens. Drug Discov. Today 12:28-33 (Pubitemid 46014477)
8. MacRae CA. 2010. Cardiac arrhythmia: In vivo screening in the zebrafish to overcome complexity in drug discovery. Expert Opin. Drug Discov. 5:619-32
9. Carpenter AE, Sabatini DM. 2004. Systematic genome-wide screens of gene function. Nat. Rev. Genet. 5:11-22 (Pubitemid 38055332)
10. St Johnston D. 2002. The art and design of genetic screens: Drosophila melanogaster. Nat. Rev. Genet. 3:176-88 (Pubitemid 34506586)
11. Patton EE, Zon LI. 2001. The art and design of genetic screens: zebrafish. Nat. Rev. Genet. 2:956-66 (Pubitemid 33691092)
12. Yeh JR, Crews CM. 2003. Chemical genetics: adding to the developmental biology toolbox. Dev. Cell 5:11-19 (Pubitemid 36827338)
13. Stockwell BR. 2000. Chemical genetics: ligand-based discovery of gene function. Nat. Rev. Genet. 1:116-25
14. Kokel D, Bryan J, Laggner C, White R, Cheung CY, et al. 2010. Rapid behavior-based identification of neuroactive small molecules in the zebrafish. Nat. Chem. Biol. 6:231-37
15. Ekker SC. 2000. Morphants: a new systematic vertebrate functional genomics approach. Yeast 17:302-6 (Pubitemid 32051423)
16. Beier DR. 1998. Zebrafish: genomics on the fast track. Genome Res. 8:9-17 (Pubitemid 28066110)
17. Nasevicius A, Ekker SC. 2001. The zebrafish as a novel system for functional genomics and therapeutic development applications. Curr. Opin. Mol. Ther. 3:224-28 (Pubitemid 32624569)
18. Shin JT, Fishman MC. 2002. From zebrafish to human: modular medical models. Annu. Rev. Genomics Hum. Genet. 3:311-40 (Pubitemid 35217440)
19. Guyon JR, Steffen LS, Howell MH, Pusack TJ, LawrenceC,Kunkel LM. 2007. Modeling human muscle disease in zebrafish. Biochim. Biophys. Acta 1772:205-15 (Pubitemid 46127824)
20. Lieschke GJ, Currie PD. 2007. Animal models of human disease: zebrafish swim into view. Nat. Rev. Genet. 8:353-67 (Pubitemid 46625809)
21. Liu NA, Huang H, Yang Z, Herzog W,Hammerschmidt M, et al. 2003. Pituitary corticotroph ontogeny and regulation in transgenic zebrafish. Mol. Endocrinol. 17:959-66 (Pubitemid 36539584)
22. Delvecchio C, Tiefenbach J, Krause HM. 2011. The zebrafish: a powerful platform for in vivo, HTS drug discovery. Assay Drug Dev. Technol. 9:354-61
23. vanHam TJ,Mapes J, Kokel D, Peterson RT. 2010. Live imaging of apoptotic cells in zebrafish. FASEB J. 24:4336-42
24. Amatruda JF, Shepard JL, Stern HM, Zon LI. 2002. Zebrafish as a cancer model system. Cancer Cell 1:229-31 (Pubitemid 41039146)
25. Langheinrich U. 2003. Zebrafish: a new model on the pharmaceutical catwalk. BioEssays 25:904-12 (Pubitemid 37081756)
26. Milan DJ, Peterson TA, Ruskin JN, Peterson RT, MacRae CA. 2003. Drugs that induce repolarization abnormalities cause bradycardia in zebrafish. Circulation 107:1355-58 (Pubitemid 36350731)
27. Anderson RH, Webb S, Brown NA, Lamers W, Moorman A. 2003. Development of the heart: (3) Formation of the ventricular outflow tracts, arterial valves, and intrapericardial arterial trunks. Heart 89:1110-18 (Pubitemid 37046862)
28. MacRae CA, Fishman MC. 2002. Zebrafish: the complete cardiovascular compendium. Cold Spring Harb. Symp. Quant. Biol. 67:301-7 (Pubitemid 36775524)
29. Ton C, Stamatiou D, Dzau VJ, Liew CC. 2002. Construction of a zebrafish cDNA microarray: gene expression profiling of the zebrafish during development. Biochem. Biophys. Res. Commun. 296:1134-42
30. Carney SA, Chen J, Burns CG, Xiong KM, Peterson RE, Heideman W. 2006. Aryl hydrocarbon receptor activation produces heart-specific transcriptional and toxic responses in developing zebrafish. Mol. Pharmacol. 70:549-61 (Pubitemid 44092316)
31. Nasevicius A, Ekker SC. 2000. Effective targeted gene "knockdown" in zebrafish. Nat. Genet. 26:216-20
32. Wienholds E, Schulte-Merker S, Walderich B, Plasterk RH. 2002. Target-selected inactivation of the zebrafish rag1 gene. Science 297:99-102 (Pubitemid 34743101)
33. Meng X, Noyes MB, Zhu LJ, Lawson ND, Wolfe SA. 2008. Targeted gene inactivation in zebrafish using engineered zinc-finger nucleases. Nat. Biotechnol. 26:695-701 (Pubitemid 351809594)
34. Foley JE, Maeder ML, Pearlberg J, Joung JK, Peterson RT, Yeh JR. 2009. Targeted mutagenesis in zebrafish using customized zinc-finger nucleases. Nat. Protoc. 4:1855-67
35. Jorgensen EM, Mango SE. 2002. The art and design of genetic screens: Caenorhabditis elegans. Nat. Rev. Genet. 3:356-69 (Pubitemid 34506717)
36. Justice MJ. 2000. Capitalizing on large-scale mouse mutagenesis screens. Nat. Rev. Genet. 1:109-15
37. Khersonsky SM, Jung DW, Kang TW, Walsh DP, Moon HS, et al. 2003. Facilitated forward chemical genetics using a tagged triazine library and zebrafish embryo screening. J. Am. Chem. Soc. 125:11804-5 (Pubitemid 37175399)
38. Peterson RT, Link BA, Dowling JE, Schreiber SL. 2000. Small molecule developmental screens reveal the logic and timing of vertebrate development. Proc. Natl. Acad. Sci. USA 97:12965-69
39. Peterson RT, Mably JD, Chen JN, Fishman MC. 2001. Convergence of distinct pathways to heart patterning revealed by the small molecule concentramide and the mutation heart-and-soul. Curr. Biol. 11:1481-91 (Pubitemid 32931009)
40. Peterson RT, Shaw SY, Peterson TA, Milan DJ, Zhong TP, et al. 2004. Chemical suppression of a genetic mutation in a zebrafish model of aortic coarctation. Nat. Biotechnol. 22:595-99 (Pubitemid 38585912)
41. Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, et al. 2008. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat. Chem. Biol. 4:33-41 (Pubitemid 350273653)
42. Yeh JR, Munson KM,Chao YL, Peterson QP,Macrae CA, Peterson RT. 2008. AML1-ETO reprograms hematopoietic cell fate by downregulating scl expression. Development 135:401-10 (Pubitemid 351228431)
43. Milan DJ, Giokas AC, Serluca FC, Peterson RT,MacRae CA. 2006. Notch1b and neuregulin are required for specification of central cardiac conduction tissue. Development 133:1125-32
44. Milan DJ, MacRae CA. 2005. Animal models for arrhythmias. Cardiovasc. Res. 67:426-37 (Pubitemid 41019550)
45. Yu PB, Deng DY, Lai CS, Hong CC, Cuny GD, et al. 2008. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat. Med. 14:1363-69
46. Hao J, Daleo MA, Murphy CK, Yu PB, Ho JN, et al. 2008. Dorsomorphin, a selective small molecule inhibitor of BMP signaling, promotes cardiomyogenesis in embryonic stem cells. PLoS ONE 3:e2904
47. Gunsalus KC, Ge H, Schetter AJ, Goldberg DS, Han JD, et al. 2005. Predictive models of molecular machines involved in Caenorhabditis elegans early embryogenesis. Nature 436:861-65 (Pubitemid 41160646)
48. Walhout AJ, Reboul J, Shtanko O, Bertin N, Vaglio P, et al. 2002. Integrating interactome, phenome, and transcriptome mapping data for the C. elegans germline. Curr. Biol. 12:1952-58 (Pubitemid 35426710)
49. Hong CC, Yu PB. 2009. Applications of small molecule BMP inhibitors in physiology and disease. Cytokine Growth Factor Rev. 20:409-18
50. Gong Z, Ju B, Wan H. 2001. Green fluorescent protein (GFP) transgenic fish and their applications. Genetica 111:213-25 (Pubitemid 34115225)
51. Carvalho L, Heisenberg CP. 2009. Imaging zebrafish embryos by two-photon excitation time-lapse microscopy. Methods Mol. Biol. 546:273-87
52. Burns CG, MacRae CA. 2006. Purification of hearts from zebrafish embryos. Biotechniques 40:278-82
53. Farber SA, Pack M, Ho SY, Johnson ID, Wagner DS, et al. 2001. Genetic analysis of digestive physiology using fluorescent phospholipid reporters. Science 292:1385-88 (Pubitemid 32476227)
54. Kumar S, Alibhai D, Margineanu A, Laine R, Kennedy G, et al. 2011. FLIM FRET technology for drug discovery: automated multiwell-plate high-content analysis, multiplexed readouts and application in situ. ChemPhysChem 12:609-26
55. Xie Y, Ottolia M, John SA, Chen JN, Philipson KD. 2008. Conformational changes of a Ca2+binding domain of the Na? exchanger monitored by FRET in transgenic zebrafish heart. Am. J. Physiol. Cell Physiol. 295:C388-93 (Pubitemid 352755764)
56. Sul JY,WuCW, Zeng F, Jochems J, LeeMT, et al. 2009. Transcriptome transfer produces a predictable cellular phenotype. Proc. Natl. Acad. Sci. USA 106:7624-29
57. Hayashi S, Akiyama S, Tamaru Y, Takeda Y, Fujiwara T, et al. 2009. A novel application ofmetabolomics in vertebrate development. Biochem. Biophys. Res. Commun. 386:268-72
58. Ong ES, Chor CF, Zou L, Ong CN. 2009. A multi-analytical approach for metabolomic profiling of zebrafish (Danio rerio) livers. Mol. Biosyst. 5:288-98
59. Trevarrow B,Robison B. 2004. Genetic backgrounds, standard lines, and husbandry of zebrafish. Methods Cell Biol. 77:599-616
60. Tran TC, Sneed B, Haider J, Blavo D,White A, et al. 2007. Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. Cancer Res. 67:11386-92 (Pubitemid 350248566)
61. Burns CG, Milan DJ, Grande EJ, Rottbauer W, MacRae CA, Fishman MC. 2005. High-throughput assay for small molecules that modulate zebrafish embryonic heart rate. Nat. Chem. Biol. 1:263-64
62. Milan DJ, Kim AM, Winterfield JR, Jones IL, Pfeufer A, et al. 2009. Drug-sensitized zebrafish screen identifies multiple genes, including GINS3, as regulators of myocardial repolarization. Circulation 120:553-59
63. Peal DS, Burns CG, Macrae CA, Milan D. 2009. Chondroitin sulfate expression is required for cardiac atrioventricular canal formation. Dev. Dyn. 238:3103-10
64. Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R. 2006. Statistical practice in high-throughput screening data analysis. Nat. Biotechnol. 24:167-75 (Pubitemid 43221699)
65. OlssonC,HolmbergA,Holmgren S. 2008. Development of enteric and vagal innervation of the zebrafish (Danio rerio) gut. J. Comp. Neurol. 508:756-70 (Pubitemid 351693559)
66. Xu X, Meiler SE, Zhong TP, Mohideen M, Crossley DA, et al. 2002. Cardiomyopathy in zebrafish due to mutation in an alternatively spliced exon of titin. Nat. Genet. 30:205-9
67. Gerull B, Gramlich M, Atherton J, McNabb M, Trombitas K, et al. 2002. Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat. Genet. 30:201-4
68. Weinstein BM, Stemple DL, Driever W, Fishman MC. 1995. gridlock, a localized heritable vascular patterning defect in the zebrafish. Nat. Med. 1:1143-47
69. Ren B, Deng Y, Mukhopadhyay A, Lanahan AA, Zhuang ZW, et al. 2010. ERK1/2-Akt1 crosstalk regulates arteriogenesis in mice and zebrafish. J. Clin. Investig. 120:1217-28
70. DeoRC, MacRae CA. 2010.Thezebrafish: scalable in vivo modeling for systems biology. Wiley Interdiscip. Rev. Syst. Biol. Med. 3:335-46
71. Foley JE, Yeh JR, Maeder ML,Reyon D, Sander JD, et al. 2009. Rapidmutation of endogenous zebrafish genes using zinc finger nucleases made by Oligomerized Pool ENgineering (OPEN). PLoS ONE 4:e4348
72. Peal DS,Mills RW, Lynch SN,Mosley JM, Lim E, et al. 2011. Novel chemical suppressors of long QT syndrome identified by an in vivo functional screen. Circulation 123:23-30
73. McAleer MF, Davidson C, DavidsonWR, Yentzer B, Farber SA, et al. 2005. Novel use of zebrafish as a vertebrate model to screen radiation protectors and sensitizers. Int. J. Radiat. Oncol. Biol. Phys. 61:10-13 (Pubitemid 40039099)
74. Lammer E, Kamp HG, Hisgen V, Koch M, Reinhard D, et al. 2009. Development of a flow-through system for the fish embryo toxicity test (FET) with the zebrafish (Danio rerio). Toxicol. In Vitro 23:1436-42
75. Augustine-Rauch K, Zhang CX, Panzica-Kelly JM. 2010. In vitro developmental toxicology assays: a review of the state of the science of rodent and zebrafish whole embryo culture and embryonic stem cell assays. Birth Defects Res. C 90:87-98
76. Brannen KC, Panzica-Kelly JM, Danberry TL, Augustine-Rauch KA. 2010. Development of a zebrafish embryo teratogenicity assay and quantitative prediction model. Birth Defects Res. B 89:66-77
77. Truong L, Harper SL, Tanguay RL. 2011. Evaluation of embryotoxicity using the zebrafish model. Methods Mol. Biol. 691:271-79
78. Roden DM. 1998. Mechanisms and management of proarrhythmia. Am. J. Cardiol. 82:491-57
79. Keating MT, Sanguinetti MC. 2001. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 104:569-80 (Pubitemid 32201951)
80. Camm AJ, Janse MJ, Roden DM, Rosen MR, Cinca J, Cobbe SM. 2000. Congenital and acquired long QT syndrome. Eur. Heart J. 21:1232-37 (Pubitemid 30487770)
81. Sanguinetti MC, Jiang C, CurranME, KeatingMT. 1995. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 81:299-307
82. Roy M, Dumaine R, Brown AM. 1996. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 94:817-23 (Pubitemid 26289240)
83. Cavero I, Mestre M, Guillon JM, Crumb W. 2000. Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin. Pharmacother. 1:947-73
84. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. 2000. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. USA 97:12329-33
85. Yang T, Snyders D, Roden DM. 2001. Drug block of Ikr: model systems and relevance to human arrhythmias. J. Cardiovasc. Pharmacol. 38:737-44 (Pubitemid 32983280)
86. Roden DM. 2001. Pharmacogenetics and drug-induced arrhythmias. Cardiovasc. Res. 50:224-31 (Pubitemid 32382149)
87. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, et al. 1999. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97:175-87
88. Furutani M, Trudeau MC, Hagiwara N, Seki A, Gong Q, et al. 1999. Novel mechanism associated with an inherited cardiac arrhythmia: defective protein trafficking by the mutant HERG (G601S) potassium channel. Circulation 99:2290-94 (Pubitemid 29201136)
89. Martin RL, McDermott JS, Salmen HJ, Palmatier J, Cox BF, Gintant GA. 2004. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J. Cardiovasc. Pharmacol. 43:369-79 (Pubitemid 38270603)
90. Davila JC, Rodriguez RJ, Melchert RB, Acosta D Jr. 1998. Predictive value of in vitro model systems in toxicology. Annu. Rev. Pharmacol. Toxicol. 38:63-96 (Pubitemid 28231489)
91. Eckardt L,Haverkamp W, BorggrefeM, BreithardtG. 1998. Experimental models of torsade de pointes. Cardiovasc. Res. 39:178-93 (Pubitemid 28322389)
92. Durham SK, Pearl GM. 2001. Computationalmethods to predict drug safety liabilities. Curr. Opin. Drug Discov. Dev. 4:110-15 (Pubitemid 32118466)
93. Warren KS, Fishman MC. 1998. "Physiological genomics": mutant screens in zebrafish. Am. J. Physiol. 275:H1-H7
94. Baker K, Warren KS, Yellen G, Fishman MC. 1997. Defective "pacemaker" current (Ih) in a zebrafish mutant with a slow heart rate. Proc. Natl. Acad. Sci. USA 94:4554-59
95. Chen JN, Haffter P, Odenthal J, Vogelsang E, Brand M, et al. 1996. Mutations affecting the cardiovascular system and other internal organs in zebrafish. Development 123:293-302 (Pubitemid 27056756)
96. Langheinrich U, VacunG,WagnerT. 2003. Zebrafish embryos express an orthologue ofHERGand are sensitive toward a range of QT-prolonging drugs inducing severe arrhythmia. Toxicol. Appl. Pharmacol. 193:370-82 (Pubitemid 37543544)
97. Shah RR, Hondeghem LM. 2005. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2:758-72 (Pubitemid 40903686)
98. Nerbonne JM, Kass RS. 2005. Molecular physiology of cardiac repolarization. Physiol. Rev. 85:1205-53 (Pubitemid 41362269)
99. Arking DE, Pfeufer A, Post W, Kao WH, Newton-Cheh C, et al. 2006. A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat. Genet. 38:644-51 (Pubitemid 43927305)
100. Shin JT, Pomerantsev EV, Mably JD, MacRae CA. 2010. High-resolution cardiovascular function confirms functional orthology of myocardial contractility pathways in zebrafish. Physiol. Genomics 42:300-9
101. Ung CY, Lam SH, Hlaing MM, Winata CL, Korzh S, et al. 2010. Mercury-induced hepatotoxicity in zebrafish: in vivo mechanistic insights from transcriptome analysis, phenotype anchoring and targeted gene expression validation. BMC Genomics 11:212
102. Hentschel DM, Park KM, Cilenti L, Zervos AS, Drummond I, Bonventre JV. 2005. Acute renal failure in zebrafish: a novel system to study a complex disease. Am. J. Physiol. Ren. Physiol. 288:F923-29 (Pubitemid 40569758)
103. Best JD, Berghmans S, Hunt JJ, Clarke SC, Fleming A, et al. 2008. Non-associative learning in larval zebrafish. Neuropsychopharmacology 33:1206-15 (Pubitemid 351367546)
104. Brockerhoff SE, Hurley JB, Janssen-Bienhold U, Neuhauss SC, Driever W, Dowling JE. 1995. A behavioral screen for isolating zebrafish mutants with visual system defects. Proc. Natl. Acad. Sci. USA 92:10545-49
105. Darland T, Dowling JE. 2001. Behavioral screening for cocaine sensitivity in mutagenized zebrafish. Proc. Natl. Acad. Sci. USA 98:11691-96 (Pubitemid 32928790)
106. Rihel J, Prober DA, Arvanites A, Lam K, Zimmerman S, et al. 2010. Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation. Science 327:348-51
107. Hanai J, Cao P, Tanksale P, Imamura S, Koshimizu E, et al. 2007. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J. Clin. Investig. 117:3940-51 (Pubitemid 350224103)
108. Berghmans S, Butler P, Goldsmith P, Waldron G, Gardner I, et al. 2008. Zebrafish-based assays for the assessment of cardiac, visual and gut function-potential safety screens for early drug discovery. J. Pharmacol. Toxicol. Methods 58:59-68
109. Field HA, Kelley KA, Martell L, Goldstein AM, Serluca FC. 2009. Analysis of gastrointestinal physiology using a novel intestinal transit assay in zebrafish. Neurogastroenterol. Motil. 21:304-12
110. Lam SH, Winata CL, Tong Y, Korzh S, LimWS, et al. 2006. Transcriptome kinetics of arsenic-induced adaptive response in zebrafish liver. Physiol. Genomics 27:351-61 (Pubitemid 46708786)
111. Liu F, Gentles A, Theodorakis CW. 2008. Arsenate and perchlorate toxicity, growth effects, and thyroid histopathology in hypothyroid zebrafish Danio rerio. Chemosphere 71:1369-76
112. Goessling W, North TE, Zon LI. 2007. New waves of discovery: modeling cancer in zebrafish. J. Clin. Oncol. 25:2473-79 (Pubitemid 46999219)
113. Taylor AM, Zon LI. 2009. Zebrafish tumor assays: the state of transplantation. Zebrafish 6:339-46
114. Koide K, Song F, de Groh ED, Garner AL, Mitchell VD, et al. 2008. Scalable and concise synthesis of dichlorofluorescein derivatives displaying tissue permeation in live zebrafish embryos. ChemBioChem 9:214-18 (Pubitemid 351196789)
115. Goldstone JV, McArthur AG, Kubota A, Zanette J, Parente T, et al. 2010. Identification and developmental expression of the full complement of Cytochrome P450 genes in zebrafish. BMC Genomics 11:643
116. Pert CB, Pasternak G, Snyder SH. 1973. Opiate agonists and antagonists discriminated by receptor binding in brain. Science 182:1359-61
117. Taunton J, Hassig CA, Schreiber SL. 1996. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272:408-11 (Pubitemid 26138177)
118. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. 2007. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol. 25:197-206 (Pubitemid 46227119)
119. Brown JC, Jones AM. 1994. Mapping the auxin-binding site of auxin-binding protein 1. J. Biol. Chem. 269:21136-40 (Pubitemid 24266486)
120. Chen JK, Lane WS, Schreiber SL. 1999. The identification of myriocin-binding proteins. Chem. Biol. 6:221-35 (Pubitemid 29368410)
121. HardingMW, Galat A, UehlingDE, Schreiber SL. 1989. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 341:758-60 (Pubitemid 19260893)
122. Miller DK, Gillard JW, Vickers PJ, Sadowski S, Leveille C, et al. 1990. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 343:278-81
123. Shimizu N, Sugimoto K, Tang J, Nishi T, Sato I, et al. 2000. High-performance affinity beads for identifying drug receptors. Nat. Biotechnol. 18:877-81 (Pubitemid 30640915)
124. Jung DW,Williams D, Khersonsky SM, Kang TW, Heidary N, et al. 2005. Identification of the F1F0 mitochondrial ATPase as a target for modulating skin pigmentation by screening a tagged triazine library in zebrafish. Mol. Biosyst. 1:85-92 (Pubitemid 43349734)
125. Moon HS, Jacobson EM, Khersonsky SM, Luzung MR, Walsh DP, et al. 2002. A novel microtubule destabilizing entity from orthogonal synthesis of triazine library and zebrafish embryo screening. J. Am. Chem. Soc. 124:11608-9
126. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, et al. 2002. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 1:376-86
127. Ross PL,HuangYN,Marchese JN, WilliamsonB,ParkerK, et al. 2004. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 3:1154-69
128. Dong W, Teraoka H, Yamazaki K, Tsukiyama S, Imani S, et al. 2002. 2,3,7,8-tetrachlorodibenzo-pdioxin toxicity in the zebrafish embryo: local circulation failure in the dorsal midbrain is associated with increased apoptosis. Toxicol. Sci. 69:191-201
129. Peterson RT, Nass R, Boyd WA, Freedman JH, Dong K, Narahashi T. 2008. Use of non-mammalian alternative models for neurotoxicological study. Neurotoxicology 29:546-55
130. Scholz S, Fischer S, GundelU, Kuster E, Luckenbach T, VoelkerD. 2008. The zebrafish embryomodel in environmental risk assessment-applications beyond acute toxicity testing. Environ. Sci. Pollut. Res. Int. 15:394-404
131. Roden DM, Altman RB, Benowitz NL, Flockhart DA, Giacomini KM, et al. 2006. Pharmacogenomics: challenges and opportunities. Ann. Intern. Med. 145:749-57 (Pubitemid 351650355)
132. Loucks E, Carvan MJ, 3rd. 2004. Strain-dependent effects of developmental ethanol exposure in zebrafish. Neurotoxicol. Teratol. 26:745-55 (Pubitemid 39296759)